Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug? [Yahoo! Finance]
Prothena Corporation plc - Ordinary Shares (PRTA)
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.prothena.com
Company Research
Source: Yahoo! Finance
Eli Lilly gained 2.6% last week and 14.1% past month. The committee said that data from clinical studies on donanemab demonstrated substantial evidence of efficacy and a clinically meaningful slowdown in disease progression for early symptomatic Alzheimer's patients. Lilly is seeking approval for donanemab for the treatment of patients with mild Alzheimer's disease. What About Competition? Notably, Biogen BIIB and its Japan-based partner Eisai's Leqembi was approved last year in the United States to reduce the cognitive decline associated with early Alzheimer's disease. Their controversial medicine, Aduhelm, was approved by the FDA in 2021. However, in January 2024, Biogen discontinued the development and commercialization of Aduhelm as the drug failed to generate any significant sales due to a lack of access to Medicare beneficiaries. Prothena Corporation PRTA, AC Immune and Cassava Sciences SAVA are also developing therapies for Alzheimer's disease. Prothena is also develo
Show less
Read more
Impact Snapshot
Event Time:
PRTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRTA alerts
High impacting Prothena Corporation plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRTA
News
- Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $84.00 price target on the stock.MarketBeat
- Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $33.00 to $31.00. They now have a "neutral" rating on the stock.MarketBeat
- Prothena Co. plc (NASDAQ: PRTA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Prothena Announces Leadership Team UpdatesBusiness Wire
- ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal [Yahoo! Finance]Yahoo! Finance
PRTA
Earnings
- 8/8/24 - Beat
PRTA
Sec Filings
- 10/3/24 - Form 3
- 10/3/24 - Form 4
- 9/27/24 - Form 8-K
- PRTA's page on the SEC website